Key Points
- Orbimed Advisors LLC sold a total of about 596,881 Sionna shares across multiple trades (roughly $26.8M), including 52,397 shares on April 17 at $44.68; after the April 17 sale it still held 2,967,722 shares (a 1.73% ownership decrease) and the transactions were executed under a pre-arranged Rule 10b5-1 plan.
- Sionna (NASDAQ:SION) trades near $41.79 with a $1.88B market cap and a one-year range of $10.97–$46.46; the company recently beat quarterly EPS estimates and carries a consensus analyst rating of "Moderate Buy" with an average price target of $50.57.
Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) Director Orbimed Advisors Llc sold 2,948 shares of the company's stock in a transaction dated Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the completion of the sale, the director directly owned 2,964,774 shares in the company, valued at $131,991,738.48. This trade represents a 0.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Orbimed Advisors Llc also recently made the following trade(s):
- On Friday, April 17th, Orbimed Advisors Llc sold 52,397 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.68, for a total transaction of $2,341,097.96.
- On Thursday, April 16th, Orbimed Advisors Llc sold 226,906 shares of Sionna Therapeutics stock. The shares were sold at an average price of $45.34, for a total transaction of $10,287,918.04.
- On Wednesday, April 15th, Orbimed Advisors Llc sold 235,863 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.64, for a total transaction of $10,528,924.32.
- On Tuesday, April 14th, Orbimed Advisors Llc sold 47,814 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.51, for a total transaction of $2,128,201.14.
- On Tuesday, February 3rd, Orbimed Advisors Llc sold 29,063 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.58, for a total transaction of $1,295,628.54.
- On Monday, February 2nd, Orbimed Advisors Llc sold 1,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.57, for a total transaction of $84,237.30.
Sionna Therapeutics Price Performance
Shares of NASDAQ SION opened at $41.79 on Wednesday. Sionna Therapeutics, Inc. has a 12-month low of $10.97 and a 12-month high of $46.46. The company has a market capitalization of $1.88 billion, a PE ratio of -21.43 and a beta of 3.01. The firm's 50-day moving average is $37.94 and its two-hundred day moving average is $38.63.
Sionna Therapeutics (NASDAQ:SION - Get Free Report) last announced its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.15. On average, analysts forecast that Sionna Therapeutics, Inc. will post -2.44 EPS for the current fiscal year.
Hedge Funds Weigh In On Sionna Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Invesco Ltd. acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $4,573,000. XTX Topco Ltd acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $203,000. Superstring Capital Management LP acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $7,430,000. Artia Global Partners LP acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $4,926,000. Finally, Balyasny Asset Management L.P. acquired a new position in Sionna Therapeutics during the fourth quarter worth approximately $58,000.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on SION. Citigroup began coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an "outperform" rating for the company. UBS Group reissued a "buy" rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Guggenheim boosted their price objective on shares of Sionna Therapeutics from $45.00 to $50.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Weiss Ratings reissued a "sell (e+)" rating on shares of Sionna Therapeutics in a research report on Monday, December 29th. Finally, Raymond James Financial reissued a "strong-buy" rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a research report on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, Sionna Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $50.57.
Check Out Our Latest Report on Sionna Therapeutics
Sionna Therapeutics Company Profile
(
Get Free Report)
Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.
At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
